Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.